Physician profile
William Tse
NPI 1922170430
$56,296.18
in general payments reported to CMS, 2019-2025
36 companies · $6,904 in 2025
The $6,904 reported for 2025 was more than what 77% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $8,912 · 2021: $2,422 · 2022: $6,785 · 2023: $720 · 2024: $7,234 · 2025: $6,904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,640 · Consulting Fee: $3,375 · Food and Beverage: $2,116 · Travel and Lodging: $1,727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,640.00 |
| Consulting Fee | $3,375.00 |
| Food and Beverage | $2,115.68 |
| Travel and Lodging | $1,726.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $22,621.36 | 2019-2020 | |
| Acrotech Biopharma INC. | $10,801.74 | 2022-2024 | Beleodaq |
| Pharmaessentia USA Corporation | $7,965.54 | 2024-2025 | Besremi |
| Astellas Pharma US INC | $5,757.02 | 2019 | |
| Celgene Corporation | $2,537.81 | 2019-2024 | Reblozyl |
| Janssen Biotech, INC. | $2,472.23 | 2019-2020 | |
| Incyte Corporation | $1,092.60 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Pfizer International LLC | $724.16 | 2024 | |
| Jazz Pharmaceuticals INC. | $421.63 | 2019-2020 | |
| Genzyme Corporation | $419.15 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $287.57 | 2019-2025 | |
| Sobi, INC | $150.78 | 2022-2025 | |
| Novocure INC. | $145.97 | 2022 | |
| Spectrum Pharmaceuticals INC. | $125.66 | 2019 | |
| Aurobindo Pharma USA, INC. | $111.20 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $84.89 | 2019-2020 | |
| Foundation Medicine, INC. | $66.60 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $64.55 | 2019-2025 | Calquence |
| Pfizer INC. | $42.74 | 2019-2025 | |
| Array Biopharma INC | $41.65 | 2025 | Xalkori, Braftovi, Lorbrena |
| Pharmacyclics LLC, An Abbvie Company | $39.41 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $36.22 | 2019 | |
| Amag Pharmaceuticals, INC. | $34.42 | 2019 | |
| Eusa Pharma (US) LLC | $29.97 | 2019 | |
| Gilead Sciences, INC. | $26.30 | 2019 | |
| Genentech USA, INC. | $25.69 | 2019 | |
| Beigene USA, INC. | $25.09 | 2023 | Brukinsa |
| Adaptive Biotechnologies Corporation | $21.71 | 2020 | |
| Abbvie INC. | $20.98 | 2025 | |
| Verastem, INC. | $17.86 | 2020 | |
| Azurity Pharmaceuticals, INC. | $17.43 | 2025 | Danziten, Vivimusta |
| Morphosys, US INC. | $14.88 | 2023 | Monjuvi |
| Teva Pharmaceuticals USA, INC. | $14.45 | 2019 | |
| Merck Sharp & Dohme LLC | $12.63 | 2020 | |
| Pharmaand Gmbh | $12.53 | 2025 | Rubraca |
| Kite Pharma, INC. | $11.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Tse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.